1. Aballea S, Chancellor J, Raikou M, Drummond M, Weinstein M, Brouard R, Jourdan S, Bridgewater JA (2005) Cost-effectiveness analysis of oxaliplatin/5-FU/LV in adjuvant treatment of colon cancer in the US. ASCO Annual Meeting, Abstract No: 194
2. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351
3. Benson 3rd AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II cancer. J Clin Oncol 22: 3408–3419
4. Briggs A, Sculpher M (1998) Introducing Markov models for economic evaluation. PharmacoEconomics 13: 397–409
5. Cassidy J, Scheithauer W, McKendrick J, Kröning H, Nowacki MP, Seitz JF, Twelves C, Van Hazel G, Wong A, Diaz-Rubio E (2004) Capecitabine versus bolus 5-FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial. ASCO Annual Meeting, Abstract No: 3509